For in vivo validation, immune-competent mouse models, such as syngeneic tumor models or humanized mice, treated with immune checkpoint inhibitors (e.g., anti-PD-1/PD-L1), will be essential to assess whether RFX1 expression influences therapeutic efficacy. This evidence concerns the gene PDCD1 and neoplasm.